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Edited by Barry HalliwellAbstract High density lipoproteins (HDL) represent a protec-
tive factor of central importance that counteracts the develop-
ment of cardiovascular disease, in part by normalizing platelet
(hyper)reactivity.
As HDL represent an eﬃcient scavenger of the naturally
occurring oxidant hypochlorite, this work was intended to inves-
tigate the inﬂuence of hypochlorite-oxidized HDL on platelet
function.
Addition of hypochlorite-oxidized HDL to human platelets re-
sults in an immediate and transient raise in intracellular calcium,
surface expression of P-selectin and platelet aggregation. The
observed eﬀects are dose dependent and can be blocked by an
antibody directed against the lipoprotein-binding domain of
platelet thrombospondin- and scavenger receptor CD36.
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Atherosclerosis represents the major source of morbidity
and mortality in the Western world. Platelets play a central
role in the development of this disease and its severe clinical
consequences like coronary artery disease and stroke. En-
hanced platelet reactivity has been demonstrated in patients
with atherosclerosis as well as in patients with established risk
factors for the development of this disease.
Today, it is accepted that atherosclerosis represents an
inﬂammatory disease [1] providing a pro-oxidative environ-
ment that forms the basis for oxidative damage of several
(lipo)proteins and cellular components, thus supplying evi-
dence (and basis) for the oxidative modiﬁcation theory of ath-
erosclerosis, originally formulated about 20 years ago.
Aside of negatively aﬀecting endothelial function and the
bioavailability of nitric oxide, oxidative stress might also be di-
rectly linked with the occurrence of platelet hyperreactivity, asAbbreviations: HDL, high density lipoproteins; hyp-OxHDL, hypo-
chlorite-oxidized HDL; nHDL; native HDL; LDL, low density
lipoproteins; MPO, myeloperoxidase; ADP, adenosine diphosphate;
f.c., ﬁnal concentration
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anisms and oxidatively modiﬁed lipids and (lipo)proteins have
been described to stimulate platelet function (recently reviewed
in [2,3]).
Lipoproteins, especially low density lipoproteins (LDL) and
high density lipoproteins (HDL), play a crucial and ambiguous
role in the development of atherosclerotic disease and the reg-
ulation of platelet function. Both classes of lipoproteins have
been described to represent easy targets for oxidative attack
and today, it is established that LDL gain their (full) athero-
genic and platelet-stimulating potential only after oxidative
modiﬁcation [1,2].
HDL, on the other hand, represent an important protective
factor. These lipoproteins have been shown to counteract
platelet activation [4], to mediate reverse cholesterol transport
[5] and to enhance synthesis and bioavailability of nitric oxide
[6]. Furthermore, HDL also possess anti-oxidative and anti-
inﬂammatory properties that are only in part attributable to
enzymatic activities residing within the lipoprotein particle [4].
Given its accepted protective functions, oxidative modiﬁca-
tion of HDL is mainly seen as an unavoidable side-eﬀect of
its function to protect other targets (e.g., LDL) from oxidative
damage. Nevertheless, the recent literature has provided com-
pelling evidence that upon oxidative modiﬁcation of HDL,
these lipoproteins not only lose important protective functions,
but also acquire severe pro-inﬂammatory and pro-thrombotic
properties. In detail, it could be shown that oxidatively modi-
ﬁed HDL interfere with reverse cholesterol transport, activate
mitogen-activated protein kinase and upregulate the expres-
sion of cyclooxygenase-2, plasminogen activator inhibitor-1
and matrix-degrading proteases in endothelial cells (reviewed
in [7]).
As oxidized HDL could be detected in vivo [8,9] and in light
of the redox-sensitive nature of platelet function, it was the aim
of this work to study the eﬀects of oxidative modiﬁcation to
HDLs (protective) properties towards platelet function.2. Material and methods
NaOCl was from Sigma–Aldrich; its concentration was determined
spectrophotometrically before use (e290 = 350 L mol
1 cm1). Acetoxy-
methyl esters of Fluo-4 and Fura Red were from Invitrogen/Molecular
Probes (Lofer, Austria).
Phycoerythrin-labeled anti-CD62P antibody was obtained from Bec-
ton Dickinson (BD Austria, Vienna, Austria).
For functional studies, azide-free antibodies were used: FA6.152 was
from Immunotech (Werfen Austria, Vienna, Austria), AT10 was from
Serotec (Du¨sseldorf, Germany).ation of European Biochemical Societies.
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content. Protein concentrations were determined by the Lowry proce-
dure [10].
Rebuﬀering was performed by size exclusion chromatography, using
EconoPac 10DG columns (Bio-Rad, Vienna, Austria).
2.1. Isolation and modiﬁcation of HDL
All manipulations were performed at 4 C. HDL (density range
1.063–1.21 g/ml) were isolated from fresh normal human acid-citrate-
dextrose plasma by sequential ﬂotation, ﬁltered (0.45 lm), and used
within 2 weeks.
Hypochlorite modiﬁcation of HDL was performed as previously de-
scribed for oxidation of LDL [11] and hyp-OxHDL were used for
experiments (or methionine-treatment) within 3 h after oxidative mod-
iﬁcation.
Methionine-treatment of hyp-OxHDL was performed by incubating
hyp-OxHDL for 10 min at room temperature with methionine
(40 mM). Subsequently, lipoproteins were rebuﬀered.
2.2. Lipoprotein analysis
Electrophoretic mobility of native and modiﬁed HDL under non-
denaturing conditions was assessed by agarose electrophoresis [12].
Relative electrophoretic mobilities were calculated as mean of values
obtained for HDL2 and HDL3.
Free amino groups were quantiﬁed ﬂuorometrically by their ability
to react with ﬂuorescamin [13]. Chloramines were quantiﬁed by the
thionitrobenzoic acid assay [14].Fig. 1. Inﬂuence of nHDL on ADP-induced expression of P-selectin: (A) AD
from 8 donors, n = 16). (f.c.: nHDL: 260 lg/ml; ADP: 2.5 lM).2.3. Platelet isolation
Freshly drawn venous blood from healthy donors was immediately
centrifuged at 125 g for 20 min to obtain platelet-rich plasma. Donors
declared to be free of any medication for at least 2 weeks.
Platelets were puriﬁed by gel-ﬁltration using a Sepharose 4B column
with HEPES-Tyrode Puﬀer containing 0.5% human serum albumin.
2.4. Platelet aggregation
Platelet aggregation was performed in an optical 4-channel aggre-
gometer (490-4D, Chronolog Corp., Havertown, PA, USA).
2.5. Quantiﬁcation of P-selectin
Surface exposure of P-selectin was determined by a FACSCalibur
ﬂow cytometer (BD Austria).
After incubation of platelets with lipoproteins and/or the indicated
amounts of platelet agonists, platelets were ﬁxed with 1% formalde-
hyde and incubated with anti-CD62P antibody for 1 h before analysis.
Incubation times were 5 min for ADP, thrombin and collagen and
10 min for lipoproteins.
2.6. Measurement of cytosolic free calcium
Free cytosolic calcium in platelets was measured by time-dependent
ﬂow cytometry. Platelet-rich plasma was incubated in the dark with
acetoxymethylester-derivatives of Fluo-4 (2 lM) and Fura Red
(4 lM) at room temperature for 45 min. Afterwards, platelets wereP; (B) ADP + nHDL; and (C) mean protective impact of nHDL (HDL
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platelet agonists were added and data acquisition was continued as
soon as practicable.
Fluo-4 signals were acquired in FL1 and Fura Red in FL3. Fluores-
cence ratio was calculated for each cell using WEASEL 2.3 software
[15].
2.7. Statistical evaluation
Results are presented as mean values plus standard deviation. Plate-
let parameters were subjected to KS test for conﬁrming normal distri-
bution and to subsequent t-tests for unpaired samples. An error
probability of less than 0.05 was considered as statistically signiﬁcant.
Experiments were performed with HDL from 8 diﬀerent donors (5
female, 3 male) and platelets from 20 diﬀerent donors (12 female, 8
male). The obtained results showed no statistically signiﬁcant gen-
der-related diﬀerences.3. Results and discussion
High density lipoproteins are known to represent an impor-
tant protective factor against the development of atherosclero-
sis and thrombosis. HDL have been shown to mediate
inhibitory eﬀects on platelet aggregation that are in part attrib-
utable to an induction of nitric oxide synthesis within platelets
[16] and stimulation of protein kinase C [17].
To provide a solid basis for subsequent experiments dealing
with oxidatively modiﬁed HDL, eﬀects of native HDL on
ADP-induced platelet activation were examined.Table 1
Physico-chemical properties of HDL from eight donors
nHDL hyp-OxHDL[75] hyp-O
Free amino groups (%) 100 50.6 ± 21.2 30.4 ±
Relative electrophoretic mobility 1 1.2 ± 0.1 1.5 ±
Chloramines per HDL 0 24.2 ± 4.4 43.3 ±
Fig. 2. Platelet aggregation triggered by hyp-OxHDL. (A) Modiﬁcation depe
OxHDL[300]; (e) ADP. (B) Concentration dependency: (a) buﬀer; (b) hyp-OxH
ml); (e) ADP (f.c. if not indicated otherwise: lipoproteins: 260 lg/ml, ADP:In line with previously published reports demonstrating pro-
tective functions of HDL towards platelet function [4,16], we
ﬁnd that native HDL signiﬁcantly impair ADP-induced sur-
face expression of P-selectin (shown in Fig. 1) and in parallel
are able to impair ADP-induced platelet aggregation (results
not shown).
Aside from their direct function on platelets and other target
cells, HDL also possess anti-oxidative properties, that are only
in part attributable to enzymatic activities residing within the
lipoproteins [18]. In this regard, HDL have been shown to rep-
resent a preferred target of oxidative attack, resulting in oxida-
tive modiﬁcation of these lipoproteins [7].
Concerning the latter, HDL have been shown to be a quite
eﬃcient scavenger of hypochlorite [19]. Hypochlorite repre-
sents a strong in vivo occurring oxidant that plays an impor-
tant role in innate immunity and inﬂammation and, as such,
also plays a pivotal role in the atherosclerotic process. Hypo-
chlorite is formed in vivo by the action of the heme enzyme
myeloperoxidase (MPO) on H2O2 in the presence of chloride
and local concentrations of hypochlorite at sites of acute
inﬂammation have been estimated to be considerably high.
The correlation between MPO levels and angiographic evi-
dence of atherosclerotic plaque [20], as well as the apparent
atheroprotective eﬀects of genetic deﬁciencies of MPO [21]
are consistent with the hypothesis that MPO participates in
the initiation and propagation of atherosclerosis.xHDL[150] hyp-OxHDL[300] Methionine-hyp-OxHDL[300]
17 15.4 ± 5.1 55.4 ± 7.3
0.1 1.7 ± 0.2 1.3 ± 0.1
7.4 62.6 ± 13.7 9.8 ± 5.4
ndency: (a) nHDL; (b) hyp-OxHDL[75]; (c) hyp-OxHDL[150]; (d) hyp-
DL (26 lg/ml); (c) hyp-OxHDL (130 lg/ml); (d) hyp-OxHDL (260 lg/
50 lM). Figures show results of a typical experiment, n = 15.
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disease, enzymatically active MPO has been identiﬁed in hu-
man atherosclerotic lesions. Immunohistochemical analysis re-
vealed colocalization of MPO- and hypochlorite-modiﬁed
proteins with apolipoprotein A-I in human atheroma. Further-
more, HDL isolated from human atheroma contains MPO as
well as several MPO-derived peptides (reviewed in [19]).
As these ﬁndings provide strong evidence for the in vivo
existence of hypochlorite-oxidized HDL (hyp-OxHDL) and
in view of the important role of (native) HDL for platelet reac-
tivity, experiments were designed to study the inﬂuence of oxi-
dative HDL-modiﬁcation by hypochlorite on the ability of
these lipoproteins to modulate platelet function.Fig. 3. P-selectin expression induced by hyp-OxHDL of diﬀerent degrees o
OxHDL[150]; (E) hyp-OxHDL[300]; (F): methionine-treated hyp-OxHDL[
statistically signiﬁcant diﬀerences to controls. (f.c.: lipoproteins: 260 lg/ml, AFor these experiments, HDL were oxidized by hypochlorite,
according to a protocol originally described for oxidation of
LDL [11]. Diﬀerent degrees of oxidative modiﬁcation of hyp-
OxHDL were obtained by varying the amount of oxidant,
resulting in the formation of hyp-OxHDL [75], hyp-OxHDL
[150] and hyp-OxHDL[300] (values in squared brackets indi-
cate the molar excess of hypochlorite). As shown in Table 1,
oxidation of HDL resulted in enhanced electrophoretic mobil-
ity of lipoproteins, formation of chloramines and a concomi-
tant decrease in the number of free amino groups (as well as
in the appearance of a certain amount of high-molecular mass
aggregates in polyacrylamide electrophoresis, the latter not
shown). The surprisingly low extent of chloramine formationf modiﬁcation: (A) control; (B) ADP; (C) hyp-OxHDL[75]; (D) hyp-
300]; and (G) means of P-selectin positive cells (n = 18). * indicates
DP: 50 lM).
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tion) is in general agreement with recently published data dem-
onstrating that – in striking contrast to the situation observed
in LDL – a signiﬁcant amount of hypochlorite is consumed by
the lipid phase of HDL3 [22].
Aggregation studies performed with gel-ﬁltered human
platelets in the presence of oxidatively modiﬁed HDL reveal
that hypochlorite-mediated oxidation converts HDL to a po-
tent platelet agonist: as shown in Fig. 2A, hyp-OxHDL are
able to trigger platelet aggregation, even in the absence of
other agonists. The amount of the observed eﬀects positively
correlates with the degree of oxidative lipoprotein modiﬁca-
tion. When stored at 4 C, hyp-OxHDL retained their plate-
let-stimulating properties for several days (not shown).
As shown in Fig. 3, incubation of platelets with hyp-OxHDL
in unstirred suspensions provokes surface expression of P-
selectin. The amount of P-selectin positive cells increases in
dependency on the degree of oxidative modiﬁcation of the em-
ployed lipoproteins. The observed increase was statistically sig-
niﬁcant for all 3 degrees of modiﬁcation.
At a given degree of modiﬁcation (shown in Fig. 2B for hyp-
OxHDL[300]), the eﬀects of hyp-OxHDL on platelet aggrega-
tion (as well as on CD62 expression, not shown) are dose
dependent. Platelet aggregation induced by hyp-OxHDL was
(for all degrees of oxidative modiﬁcation and at any lipopro-
tein concentration tested) always irreversible and did not de-
pend on the presence of exogenously added ﬁbrinogen.
Oxidative modiﬁcation of proteins by hypochlorite results in
the formation of chloramines. As a consequence of their semi-
stable nature, chloramine formation can be reversed by several
thiol- and thioether-containing molecules. Accordingly, when
hyp-OxHDL were incubated with excess methionine, this
treatment resulted in almost complete elimination of lipopro-
tein-associated chloramines and partial recovery of free amino
groups (shown in Table 1).Fig. 4. Attenuation of hyp-OxHDL induced platelet aggregation. (A) After
treated hyp-OxHDL[300]; (b) hyp-OxHDL + nHDL (540 lg/ml); (c) hyp-O
antibody FA6.152 (10 lg/ml): (a) control; (b) FA6 + hyp-OxHDL; (c) hyp
lipoproteins: 260 lg/ml, ADP: 50 lM). Figures show results of a typical expExperiments performed with such methionine-treated hyp-
OxHDL show that, upon methionine-treatment and elimina-
tion of chloramines, hyp-OxHDL completely lose both their
ability to trigger platelet aggregation (depicted in Fig. 4A, trac-
ing a) and to induce surface expression of P-selectin (shown in
Fig. 3F).
Although elimination of chloramines coincides with a loss of
platelet-stimulating properties of hyp-OxHDL, this ﬁnding
does not necessarily implicate chloramine(-deﬁned epitope)s
to be responsible for the observed platelet-activating eﬀects
of hypochlorite-oxidized HDL. On the basis of our current
ﬁndings we cannot exclude the possibility that during hypo-
chlorite-mediated oxidation of HDL epitopes/compounds are
formed that are not related to chloramines but nevertheless
are redox-sensitive.
In light of the protective nature of native HDL (nHDL) on
platelet (hyper)reactivity, additional experiments were per-
formed concerning the inﬂuence of nHDL on platelet aggrega-
tion induced by hyp-OxHDL.
Fig. 4A shows tracings of a typical experiment: in a dose
dependent way, nHDL are able to impede platelet aggregation
induced by hyp-OxHDL, thereby further emphasizing the pro-
tective role of nHDL towards diﬀerent platelet agonists.
Nevertheless, the possibility exists that nHDL (also) impede
hyp-OxHDL induced platelet aggregation by competing with
hyp-OxHDL for speciﬁc binding to receptors on the platelet
surface.
In this regard, it is of special interest that platelet thrombo-
spondin- (and putative HDL-) receptor CD36 represents a
class B scavenger receptor and as such, CD36 is capable of
interacting with a variety of seemingly unrelated ligands,
among them several types of native and modiﬁed lipopro-
teins [23]. In transfected cell lines, CD36-mediated binding
of trace metal – oxidized HDL has been reported recently
[24].methionine-treatment and in the presence of nHDL: (a) methionine-
xHDL + nHDL (260 lg/ml); (d) hyp-OxHDL. (B) In the presence of
-OxHDL; (d) FA6 + ADP; (e) ADP (f.c. if not indicated otherwise:
eriment, n = 15.
A. Assinger et al. / FEBS Letters 582 (2008) 778–784 783To test the hypothesis that scavenger receptor CD36 is
involved in the observed eﬀects mediated by hyp-OxHDL,
experiments with the monoclonal antibody FA6.152 were
performed, as this antibody (by binding to a domain of
CD36 deﬁned by amino acids 155–183) eﬀectively interferes
with binding of VLDL, HDL, LDL as well as with binding
of (at least some types of) modiﬁed lipoproteins to CD36 [23].
Notably, the presence of antibody FA6.152 in stirred platelet
suspensions leads to platelet aggregation (not shown) that is
triggered by interaction of the Fc-portion of this antibody with
platelet Fc-gamma receptor CD32. Therefore, aggregation
experiments in the presence of this antibody can only be per-
formed after blocking CD32 by an appropriate antibody. In
a previously published study we were able to show that the
monoclonal antibody AT10 prevents CD32-mediated platelet
aggregation induced by Fc-portions of diﬀerent antibodies,
but does not aﬀect other forms of platelet aggregation [25].
As AT10 indeed also prevented CD32-mediated platelet
aggregation induced by FA6.152, a combination of these anti-
bodies was used for subsequent aggregation experiments.Fig. 5. Intracellular free calcium. (A) Fluo-4 ﬂuorescence after addition of i
Red) of calcium inﬂux induced by ADP and hyp-OxHDL (f.c.: lipoproteins:
n(hyp-OxHDL) = 8; n(experiments) = 24.As shown in Fig. 4B, antibody FA6.152 (as outlined above,
in combination with 3 lg/ml AT10) completely blocks platelet
aggregation induced by hyp-OxHDL. Control experiments
show that the presence of both antibodies in platelet suspen-
sions does not inﬂuence aggregation responses induced by
ADP. Furthermore, addition of CD32-blocking antibody
AT10 alone proves to be without eﬀect on ADP – as well as
on hyp-OxHDL – induced platelet aggregation (not shown).
Measurements of intraplatelet levels of free calcium reveal
that the addition of hyp-OxHDL to unstirred platelet suspen-
sions results in an immediate calcium inﬂux with kinetics that
are comparable to those observed after addition of ADP (see
Fig. 5A). In accordance with results obtained from aggrega-
tion experiments, antibody FA6.152 prevents calcium inﬂux
provoked by hyp-OxHDL, but does not aﬀect calcium inﬂux
in response to ADP (depicted in Fig. 5B), thereby providing
further evidence for a possible role of CD36 in platelet activa-
tion by hyp-OxHDL. Notably, as these experiments were per-
formed with unstirred platelet suspensions, it was possible to
omit antibody AT10 from these experiments. Nevertheless,ndicated agonists; (B) inﬂuence of FA6 on sliding mean (Fluo-4/ Fura
260 lg/ml, ADP: 50 lM). Figure shows results of a typical experiment:
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tical in absence and presence of AT10.
Taken together, we have shown that upon oxidation by the
in vivo occurring oxidant hypochlorite, HDL lose their protec-
tive role on platelet function and acquire strong platelet-stimu-
lating properties. In this regard, it is of special interest that
hypochlorite-oxidized HDL3 – while showing no eﬀect on
platelet aggregation in platelet-rich plasma [26] – have been re-
ported to decrease intraplatelet calcium by stimulating plasma
membrane Ca(2+)-ATPase activity [27]. Several reasons might
account for discrepancies to the ﬁndings reported herein, as
both the degree of oxidative modiﬁcation (molar excess of
hypochlorite over lipoproteins 300 vs. 200) and lipoprotein
concentrations (260 lg/ml vs. 25 lg/ml) were higher in our
experiments than in those reported in Ref. [27]. Notably, at
100 lg/ml, hypochlorite-oxidized HDL3 were reported to lose
their ability to decrease intraplatelet calcium (shown in Fig. 3
of Ref. [27]) and therefore, (also) biphasic eﬀects of hyp-
OxHDL3 might represent a plausible cause for these contradic-
tory ﬁndings. From preliminary experiments we can exclude the
possibility that eﬀects of hyp-OxHDL on platelet function
fundamentally diﬀer from those of oxidized sub-class HDL3.
The ﬁnding that oxidation by the in vivo occurring oxidant
hypochlorite converts HDL into a strong platelet agonist
represents an important ﬁnding. Myeloperoxidase and myelo-
peroxidase-derived hypochlorite play a central role in
atherosclerosis and (other forms of) systemic inﬂammation
and these diseases coincide with enhanced platelet reactivity.
Local concentrations of hypochlorite at sites of acute inﬂam-
mation have been calculated to be 340 lM and higher [28].
Therefore, the extent of oxidative modiﬁcation of hyp-OxHDL
used in this study would be estimated to be roughly compara-
ble to the degree of (subendothelial) HDL modiﬁcation that
might occur in vivo.References
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